Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Public ClinicalTrials.gov record NCT03014622. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
Study identification
- NCT ID
- NCT03014622
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 303 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2016 (Actual)
- Primary completion
- Nov 14, 2017 (Actual)
- Completion
- Nov 14, 2017 (Actual)
- Last update posted
- Jul 21, 2022
2016 – 2017
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35205 | — |
| Not listed | Beverly Hills | California | 90210 | — |
| Not listed | Newport Beach | California | 92663 | — |
| Not listed | San Francisco | California | 94117 | — |
| Not listed | Santa Monica | California | 90404 | — |
| Not listed | Greenwood | Colorado | 80111 | — |
| Not listed | Boca Raton | Florida | 33431 | — |
| Not listed | Coral Gables | Florida | 33146 | — |
| Not listed | Chestnut Hill | Massachusetts | 02467 | — |
| Not listed | Birmingham | Michigan | 48009 | — |
| Not listed | Montclair | New Jersey | 07042 | — |
| Not listed | New York | New York | 10001 | — |
| Not listed | New York | New York | 10022 | — |
| Not listed | Chapel Hill | North Carolina | 27517 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03014622, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2022 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03014622 live on ClinicalTrials.gov.